000			02931nam a22002657a 4500
001			R000760
003			PILC
005			20240805143616.0
008			240805b |||||||| |||| 00| 0 eng d
040			_beng _cFEU-NRMF MEDICAL LIBRARY _erda
041			_aeng
050			_aOB 2023 0006
245			_aEffects of Oral Dydrogesterone and Oral Medroxyprogesterone Acetate in the Treatment of Abnormal Uterine Bleeding-Ovulatory Dysfunction in ReproductiveAged Women from 18 to 39 years old: A Five-Year Chart Review / _b[author]: Palabrica, Nicolette Vanesa L. [co-author]: Reyes, Lylah D.
260			_aFairview, Quezon City: _bDepartment of OBgyne, FEU-NRMF, _c2023
300			_c( in folder) _ewith flash drive (soft copy)
336			_2rdacontent _atext
337			_2rdamedia _aunmediated
338			_2rdacarrier _avolume
504			_aIncludes bibliographical references.
520			_aABSTRACT: Background: Anovulatory cycles possess an estrogenic endometrium with absence of progesterone to regulate and organize the endometrium. Hence, one treatment approach for ovulatory dysfunction is the use of progestins to have a scheduled and well-ordered withdrawal bleeding. Objective: Compare the effects of oral dydrogesterone and oral medroxyprogesterone acetate in the treatment of abnormal uterine bleeding-ovulatory dysfunction among reproductive aged women from 18 to 39 years from 2016 to 2020. Methods: A five-year retrospective cohort which reviewed charts of women with abnormal uterine bleeding-ovulatory dysfunction who were either given oral dydrogesterone or medroxyprogesterone acetate. Data extracted were patient’s age, gravidity, parity, progesterone agent used, menstrual cycle regularity, frequency of menses, duration of menses, menstrual blood loss score and its adverse effects. Purposive Sampling done. Chi-square and t-test were used to compare the effects of the two progestins. Result: Eligible for review were 310 charts of women who received oral progestin with 155 cases for each arm. After the 6-month treatment, Dydrogesterone and Medroxyprogesterone acetate both resulted to regular, as well as normal menstrual cycle frequency, duration of menses, and menstrual blood loss (p < 0.05). Their effect on mean frequency, cycle variation, duration, and blood loss volume were comparable.Reported adverse effects were also similar, 46.5% (87) for those with Dydrogesterone and 53.4% (100) with Oral Medroxyprogesterone acetate (p 0.31). Conclusion: Oral Dydrogesterone and Oral Medroxyprogesterone Acetate when used for treatment of AUB-0 have comparable effects on the menstrual parameters and reported adverse effects. Keywords: Abnormal Uterine Bleeding, AUB-O, Ovulatory Dysfunction, Oral Medroxyprogesterone Acetate, Oral Dyrogesterone
521			_aisha _aRESDOG
700			_4Palabrica, Nicolette Vanesa L. _aauthor
700			_4Reyes, Lylah D. _aco-author
942			_2lcc _cRU
999			_c12945 _d12945